Multivariate Cox regression analysis of predictors of acquiring PSA infection
| B | SE | Df | Sig. | HR | 95% CI for HR | ||
| Lower | Upper | ||||||
| Age | 0.025 | 0.081 | 1 | 0.758 | 1.03 | 0.88 | 1.20 |
| Basal mMRC dyspnoea scale | 0.340 | 0.112 | 1 | 0.002* | 1.41 | 1.13 | 1.75 |
| FEV1% predicted | −0.182 | 0.088 | 1 | 0.038* | 0.83 | 0.70 | 0.99 |
| Systemic corticosteroids use† | −0.254 | 0.187 | 1 | 0.175 | 0.78 | 0.54 | 1.12 |
| ICS use | −0.499 | 0.433 | 1 | 0.249 | 0.61 | 0.26 | 1.42 |
| ICS dose‡ | 0.232 | 0.113 | 1 | 0.040* | 1.26 | 1.01 | 1.57 |
*Significant p≤0.05.
†Systemic corticosteroids use>3 courses during the follow-up duration (2012–2020).
‡Fluticasone propionate equivalents (daily dose).
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; mMRC, modified medical research council; PsA, Pseudomonas aeruginosa.